Oculis (NASDAQ:OCS) Trading Down 6% – Should You Sell?

Shares of Oculis Holding AG (NASDAQ:OCS) traded down 6% during mid-day trading on Monday . The company traded as low as $20.10 and last traded at $20.3850. 74,697 shares traded hands during mid-day trading, an increase of 35% from the average session volume of 55,225 shares. The stock had previously closed at $21.68.

Analyst Ratings Changes

Several analysts have recently weighed in on OCS shares. Lifesci Capital assumed coverage on shares of Oculis in a research report on Wednesday, December 3rd. They set an “outperform” rating and a $55.00 target price on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Oculis in a report on Wednesday, October 8th. Wall Street Zen raised Oculis from a “sell” rating to a “hold” rating in a research note on Saturday, November 15th. HC Wainwright increased their price objective on Oculis from $36.00 to $42.00 and gave the stock a “buy” rating in a research note on Tuesday, November 11th. Finally, Bank of America reduced their price target on shares of Oculis from $30.00 to $29.00 and set a “buy” rating on the stock in a research report on Thursday, November 13th. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $42.33.

Oculis Price Performance

The company has a quick ratio of 4.47, a current ratio of 4.47 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $1.08 billion, a price-to-earnings ratio of -8.17 and a beta of 0.32. The stock’s 50-day moving average price is $19.77 and its 200-day moving average price is $18.78.

Oculis (NASDAQ:OCS) last posted its quarterly earnings data on Monday, November 10th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.50) by $0.10. The firm had revenue of $0.31 million for the quarter, compared to the consensus estimate of $0.23 million. Oculis had a negative return on equity of 80.82% and a negative net margin of 12,915.42%. Equities research analysts anticipate that Oculis Holding AG will post -2.09 earnings per share for the current year.

Institutional Investors Weigh In On Oculis

Several institutional investors have recently modified their holdings of OCS. Pivotal bioVenture Partners Investment Advisor LLC lifted its holdings in Oculis by 32.4% during the first quarter. Pivotal bioVenture Partners Investment Advisor LLC now owns 2,300,774 shares of the company’s stock worth $43,784,000 after acquiring an additional 563,078 shares in the last quarter. SR One Capital Management LP acquired a new stake in shares of Oculis during the first quarter worth about $6,137,000. Aberdeen Group plc raised its position in shares of Oculis by 24.1% during the first quarter. Aberdeen Group plc now owns 1,253,119 shares of the company’s stock worth $23,847,000 after purchasing an additional 243,695 shares during the period. Alyeska Investment Group L.P. bought a new position in shares of Oculis during the 1st quarter valued at about $2,499,000. Finally, Woodline Partners LP grew its position in shares of Oculis by 65.8% in the 3rd quarter. Woodline Partners LP now owns 83,833 shares of the company’s stock valued at $1,474,000 after purchasing an additional 33,265 shares during the period. Institutional investors and hedge funds own 22.30% of the company’s stock.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.